• Anjali SharmaEmail author


Overweight and obesity prevalence rates among HIV-infected persons in western nations are comparable to those in uninfected populations and as high as 65%. Modest weight gain has been reported with HAART use, which may confer additional risk of developing cardiovascular disease and diabetes, particularly in those with greater pre-ART BMI. Visceral adipose tissue (VAT), in both intra-abdominal and epicardial depots, has been implicated as an independent risk factor for conditions such as insulin resistance, diabetes, hepatic steatosis, dyslipidemia, and hypertension and more recently in the development of subclinical atherosclerosis and adverse cardiovascular outcomes. Therapeutic strategies aimed at reducing VAT may hold particular promise in reducing disease in aging HIV-infected persons, in whom disorders of body composition and premature cardiovascular disease develop frequently.


Obesity Overweight Central obesity Visceral adipose tissue Epicardial adipose tissue 


  1. 1.
    Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDs. 2008;22(12):925–30.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Hodgson LM, Ghattas H, Pritchitt H, Schwenk A, Payne L, Macallan DC. Wasting and obesity in HIV outpatients. AIDS (London, England). 2001;15(17):2341–2.CrossRefGoogle Scholar
  3. 3.
    Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Boodram B, Plankey MW, Cox C, Tien PC, Cohen MH, Anastos K, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women’s Interagency HIV Study. AIDS Patient Care STDs. 2009;23(12):1009–16.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39(5):557–61.PubMedGoogle Scholar
  6. 6.
    Tedaldi EM, Brooks JT, Weidle PJ, Richardson JT, Baker RK, Buchacz K, et al. Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2006;43(1):35–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Crum-Cianflone N, Roediger MP, Eberly L, Headd M, Marconi V, Ganesan A, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5(4):e10106.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC, et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012;17(7):1281–9.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Taylor BS, Liang Y, Garduno LS, Walter EA, Gerardi MB, Anstead GM, et al. High risk of obesity and weight gain for HIV-infected uninsured minorities. J Acquir Immune Defic Syndr. 2014;65(2):e33–40.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Sharma A, Bynum SA, Schneider MF, Cox C, Tien PC, Hershow RC, et al. Changes in body mass index following HAART initiation among HIV-infected women in the Women’s Interagency HIV Study. J AIDS Clin Res. 2014;5:1000323.Google Scholar
  11. 11.
    Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retrovir. 2016;32(1):50–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Hasse B, Iff M, Ledergerber B, Calmy A, Schmid P, Hauser C, et al. Obesity trends and body mass index changes after starting antiretroviral treatment: The Swiss HIV Cohort Study. Open Forum Infect Dis. 2014;1(2):ofu040.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.PubMedCrossRefGoogle Scholar
  14. 14.
    Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (London, England). 2003;17(7):971–9.CrossRefGoogle Scholar
  15. 15.
    Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis. 2004;39(8):1223–30.PubMedCrossRefGoogle Scholar
  16. 16.
    Guehi C, Badje A, Gabillard D, Ouattara E, Koule SO, Moh R, et al. High prevalence of being overweight and obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano trial. AIDS Res Ther. 2016;13:12.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retrovir. 2013;29(3):435–40.PubMedCrossRefGoogle Scholar
  18. 18.
    Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60(12):1852–9.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Shor-Posner G, Campa A, Zhang G, Persaud N, Miguez-Burbano MJ, Quesada J, et al. When obesity is desirable: a longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort. J Acquir Immune Defic Syndr. 2000;23(1):81–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Shuter J, Chang CJ, Klein RS. Prevalence and predictive value of overweight in an urban HIV care clinic. J Acquir Immune Defic Syndr. 2001;26(3):291–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Jones CY, Hogan JW, Snyder B, Klein RS, Rompalo A, Schuman P, et al. Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. Clin Infect Dis. 2003;37(Suppl 2):S69–80.PubMedCrossRefGoogle Scholar
  22. 22.
    Guenter P, Muurahainen N, Simons G, Kosok A, Cohan GR, Rudenstein R, et al. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr. 1993;6(10):1130–8.PubMedGoogle Scholar
  23. 23.
    Suttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, Muller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(3):239–46.PubMedCrossRefGoogle Scholar
  24. 24.
    Melchior JC, Niyongabo T, Henzel D, Durack-Bown I, Henri SC, Boulier A. Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition (Burbank, Los Angeles County, Calif). 1999;15(11–12):865–9.CrossRefGoogle Scholar
  25. 25.
    Chlebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol. 1989;84(10):1288–93.PubMedGoogle Scholar
  26. 26.
    Argemi X, Dara S, You S, Mattei JF, Courpotin C, Simon B, et al. Impact of malnutrition and social determinants on survival of HIV-infected adults starting antiretroviral therapy in resource-limited settings. AIDS (London, England). 2012;26(9):1161–6.CrossRefGoogle Scholar
  27. 27.
    Paton NI, Sangeetha S, Earnest A, Bellamy R. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy. HIV Med. 2006;7(5):323–30.PubMedCrossRefGoogle Scholar
  28. 28.
    Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Maskew M, Brennan AT, Westreich D, McNamara L, MacPhail AP, Fox MP. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt). 2013;22(2):113–20.CrossRefGoogle Scholar
  30. 30.
    May M, Boulle A, Phiri S, Messou E, Myer L, Wood R, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (London, England). 2010;376(9739):449–57.PubMedCentralCrossRefGoogle Scholar
  31. 31.
    Sharma A, Hoover DR, Shi Q, Gustafson D, Plankey MW, Hershow RC, et al. Relationship between body mass index and mortality in HIV-infected HAART users in the Women’s Interagency HIV Study. PLoS One. 2015;10(12):e0143740.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda (MD): National Heart, Lung, and Blood Institute; 1998. Available from:
  33. 33.
    Berrahmoune H, Herbeth B, Samara A, Marteau JB, Siest G, Visvikis-Siest S. Five-year alterations in BMI are associated with clustering of changes in cardiovascular risk factors in a gender-dependant way: the Stanislas study. Int J Obes. 2008;32(8):1279–88.CrossRefGoogle Scholar
  34. 34.
    Fransson EI, Batty GD, Tabak AG, Brunner EJ, Kumari M, Shipley MJ, et al. Association between change in body composition and change in inflammatory markers: an 11-year follow-up in the Whitehall II Study. J Clin Endocrinol Metab. 2010;95(12):5370–4.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Alley DE, Chang VW. Metabolic syndrome and weight gain in adulthood. J Gerontol A Biol Sci Med Sci. 2010;65(1):111–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17(9):961–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Vistisen D, Witte DR, Tabak AG, Herder C, Brunner EJ, Kivimaki M, et al. Patterns of obesity development before the diagnosis of type 2 diabetes: the Whitehall II cohort study. PLoS Med. 2014;11(2):e1001602.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol. 2009;54(14):1209–27.PubMedCrossRefGoogle Scholar
  39. 39.
    Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, Steyerberg EW, et al. Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check? Arch Intern Med. 2010;170(1):27–40.PubMedCrossRefGoogle Scholar
  40. 40.
    Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93(2):172–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ (Clinical research ed). 2007;335(7611):136.PubMedCentralCrossRefGoogle Scholar
  42. 42.
    Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ (Clinical research ed). 2008;336(7659):1475–82.CrossRefGoogle Scholar
  43. 43.
    Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (London, England). 2011;377(9771):1085–95.CrossRefGoogle Scholar
  44. 44.
    De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31(6):1224–9.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Herrin M, Tate JP, Akgun KM, Butt AA, Crothers K, Freiberg MS, et al. Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr. 2016;73(2):228–36.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255–68.PubMedCrossRefGoogle Scholar
  47. 47.
    Koethe JR, Jenkins CA, Turner M, Bebawy S, Shepherd BE, Wester CW, et al. Body mass index and the risk of incident noncommunicable diseases after starting antiretroviral therapy. HIV Med. 2015;16(1):67–72.PubMedCrossRefGoogle Scholar
  48. 48.
    Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89(6):2595–600.CrossRefPubMedGoogle Scholar
  50. 50.
    Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed). 1984;288(6428):1401–4.CrossRefGoogle Scholar
  51. 51.
    Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280(21):1843–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73(7):460–8.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Li TY, Rana JS, Manson JE, Willett WC, Stampfer MJ, Colditz GA, et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation. 2006;113(4):499–506.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (London, England). 2005;366(9497):1640–9.CrossRefGoogle Scholar
  55. 55.
    Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation. 2000;102(2):179–84.PubMedCrossRefGoogle Scholar
  56. 56.
    Czernichow S, Bruckert E, Bertrais S, Galan P, Hercberg S, Oppert JM. Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men. Int J Obes. 2007;31(5):791–6.CrossRefGoogle Scholar
  57. 57.
    Tanko LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005;111(15):1883–90.PubMedCrossRefGoogle Scholar
  58. 58.
    Arsenault BJ, Lemieux I, Despres JP, Wareham NJ, Kastelein JJ, Khaw KT, et al. The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. CMAJ. 2010;182(13):1427–32.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    de Graaf FR, Schuijf JD, Scholte AJ, Djaberi R, van Velzen JE, Roos CJ, et al. Usefulness of hypertriglyceridemic waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography. Am J Cardiol. 2010;106(12):1747–53.PubMedCrossRefGoogle Scholar
  60. 60.
    Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301–13.PubMedCrossRefGoogle Scholar
  61. 61.
    Lemieux I, Poirier P, Bergeron J, Almeras N, Lamarche B, Cantin B, et al. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? Can J Cardiol. 2007;23(Suppl B):23b–31b.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Enzi G, Gasparo M, Biondetti PR, Fiore D, Semisa M, Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr. 1986;44(6):739–46.CrossRefPubMedGoogle Scholar
  63. 63.
    Seidell JC, Oosterlee A, Deurenberg P, Hautvast JG, Ruijs JH. Abdominal fat depots measured with computed tomography: effects of degree of obesity, sex, and age. Eur J Clin Nutr. 1988;42(9):805–15.PubMedGoogle Scholar
  64. 64.
    Schwartz RS, Shuman WP, Bradbury VL, Cain KC, Fellingham GW, Beard JC, et al. Body fat distribution in healthy young and older men. J Gerontol. 1990;45(6):M181–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Kotani K, Tokunaga K, Fujioka S, Kobatake T, Keno Y, Yoshida S, et al. Sexual dimorphism of age-related changes in whole-body fat distribution in the obese. Int J Obes Relat Metab Disord. 1994;18(4):207–2.PubMedGoogle Scholar
  66. 66.
    Pascot A, Lemieux S, Lemieux I, Prud’homme D, Tremblay A, Bouchard C, et al. Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women. Diabetes Care. 1999;22(9):1471–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–7.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150–9.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Huffman DM, Barzilai N. Role of visceral adipose tissue in aging. Biochim Biophys Acta. 2009;1790(10):1117–23.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005;39(4):395–400.PubMedCrossRefGoogle Scholar
  71. 71.
    Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA. 2006;296(7):844–54.PubMedCrossRefGoogle Scholar
  72. 72.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis. 2005;41(11):1662–70.PubMedCrossRefGoogle Scholar
  73. 73.
    Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32(1):48–56.PubMedCrossRefGoogle Scholar
  74. 74.
    Shikuma CM, Waslien C, McKeague J, Baker N, Arakaki M, Cui XW, et al. Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. AIDS (London, England). 1999;13(11):1359–65.CrossRefGoogle Scholar
  75. 75.
    Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48–62.PubMedCrossRefGoogle Scholar
  76. 76.
    Crane HM, Grunfeld C, Harrington RD, Kitahata MM. Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med. 2009;10(8):496–503.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Villarroya F, Domingo P, Giralt M. Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim Biophys Acta. 2010;1801(3):392–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, Ligabue G, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis. 2010;208(1):222–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Gabriella O, Giovanni G, Stefano Z, Federica C, Pietro B, Marianna M, et al. Ectopic fat is linked to prior cardiovascular events in men with HIV. J Acquir Immune Defic Syndr. 2012;59(5):494–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Guaraldi G, Zona S, Orlando G, Carli F, Ligabue G, Fiocchi F, et al. Progression of coronary artery calcium in men affected by human immunodeficiency virus infection. Int J Cardiovasc Imaging. 2012;28(4):935–41.PubMedCrossRefGoogle Scholar
  81. 81.
    Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr. 2009;22(12):1311–9; quiz 417–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Malavazos AE, Ermetici F, Cereda E, Coman C, Locati M, Morricone L, et al. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis. 2008;18(8):523–30.PubMedCrossRefGoogle Scholar
  83. 83.
    Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med. 2005;2(10):536–43.PubMedCrossRefGoogle Scholar
  84. 84.
    Eroglu S, Sade LE, Yildirir A, Bal U, Ozbicer S, Ozgul AS, et al. Epicardial adipose tissue thickness by echocardiography is a marker for the presence and severity of coronary artery disease. Nutr Metab Cardiovasc Dis. 2009;19(3):211–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Ahn SGLH, Joe DY, Kang SJ, Choi BJ, Choi SY. Relationship of epicardial adipose tissue by echocardiography to coronary artery disease. Heart. 2008;94:e7.PubMedCrossRefGoogle Scholar
  86. 86.
    Ding JHF, Harris TB, Liu Y, Kritchevsky SB, Szklo M, Ouyang P, Espeland MA, Lohman KK, Criqui MH, Allison M, Bluemke DA, Carr JJ. The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr. 2009;90(3):499–504.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Gorter PM dVA, van der Graaf Y, Stella PR, Doevendans PA, Meijs MF, Prokop M, Visseren FL. Relation of epicardial and pericoronary fat to coronary atherosclerosis and coronary artery calcium in patients undergoing coronary angiography. Am J Cardiol. 2008;102(4):380–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Natale FTM, Mocerino R, de Simone V, Di Marco GM, Aronne L, Credendino M, Siniscalchi C, Calabrò P, Cotrufo M, Calabrò R. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. Eur J Echocardiogr. 2009;10:549–55.PubMedCrossRefGoogle Scholar
  89. 89.
    Iacobellis G, Pellicelli AM, Sharma AM, Grisorio B, Barbarini G, Barbaro G. Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. Am J Cardiol. 2007;99(10):1470–2.PubMedCrossRefGoogle Scholar
  90. 90.
    Iacobellis G, Sharma AM, Pellicelli AM, Grisorio B, Barbarini G, Barbaro G. Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res. 2007;5(2):275–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Lo J, Abbara S, Rocha-Filho JA, Shturman L, Wei J, Grinspoon SK. Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. AIDS (London, England). 2010;24(13):2127–30.CrossRefGoogle Scholar
  92. 92.
    Guaraldi G, Scaglioni R, Zona S, Orlando G, Carli F, Ligabue G, et al. Epicardial adipose tissue is an independent marker of cardiovascular risk in HIV-infected patients. AIDS (London, England). 2011;25(9):1199–205.CrossRefGoogle Scholar
  93. 93.
    Brener M, Ketlogetswe K, Budoff M, Jacobson LP, Li X, Rezaeian P, et al. Epicardial fat is associated with duration of antiretroviral therapy and coronary atherosclerosis. AIDS (London, England). 2014;28(11):1635–44.CrossRefGoogle Scholar
  94. 94.
    Zona S, Raggi P, Bagni P, Orlando G, Carli F, Ligabue G, et al. Parallel increase of subclinical atherosclerosis and epicardial adipose tissue in patients with HIV. Am Heart J. 2012;163(6):1024–30.PubMedCrossRefGoogle Scholar
  95. 95.
    Raggi P, Zona S, Scaglioni R, Stentarelli C, Ligabue G, Besutti G, et al. Epicardial adipose tissue and coronary artery calcium predict incident myocardial infarction and death in HIV-infected patients. J Cardiovasc Comput Tomogr. 2015;9(6):553–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Divisions of General Internal Medicine and Infectious Diseases, Department of MedicineAlbert Einstein College of MedicineBronxUSA

Personalised recommendations